الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
Head and neck cancer accounts for more than 780,000 cases annually worldwide
The main risk factors include tobacco and alcohol use and HPV virus infection.
Most of patients present with late stage disease with the cure rates reach only 30%.
Despite aggressive treatments with combinations of surgery, radiation and chemotherapy, little progress has been made towards better outcomes.
The care for patients with HNSCC has always been a trade-off between maximizing curative potential while minimizing therapy-related morbidity, and the stepwise advances in multidisciplinary care resulting in current standard therapeutic approaches that have resulted from decades of clinical research.
The Meta Analysis of Chemotherapy on Head and Neck Cancer (MACH-NC) demonstrated that adding chemotherapy to radiotherapy in both definitive and adjuvant postoperative settings resulted in a 12% reduction in the risk of death from HNSCC, corresponding to an absolute improvement of 4% in 5 years survival.
Multiple different chemotherapy regimens have been used but the most common regimens include a platinum-containing agent, either cisplatin or carboplatin. Data regarding the superiority of one agent over another are scarce
Weekly cisplatin could be easier to manage than three-weekly cisplatin, because patients can be monitored more regularly for toxicity allowing the schedule to be altered if required. This regimen appears to be a suitable alternative to three-weekly high-dose cisplatin with concomitant radiotherapy.
Carboplatin may be associated with fewer complications than cisplatin in CCRT regimens, and could therefore offer a reasonable alternative; however, comparative data are somewhat limited.
The present study was undertaken to determine any difference in the response rates, locoregional control rates and progression free survival outcome in two groups of patients of advanced cancer of head and neck receiving concomitant radiotherapy with Cisplatin and carboplatin.
The selection of the optimal platinum analogue to be employed is dependent on the type of tumor.
The treatment intention (palliative vs. curative)
Schedule regimen
The other component drugs being used in combination.